Do Kim
Stock Analyst at Piper Sandler
(2.02)
# 3,055
Out of 4,980 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $64.40 | -2.17% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $21.64 | +112.57% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $396.48 | -25.34% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $115.76 | -3.25% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $19.46 | +347.07% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.45 | +838.78% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $35.93 | -44.34% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $5.82 | +638.83% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $38.28 | -16.41% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $4.24 | +418.87% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $31.58 | -39.84% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $3.35 | +377.61% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $482.13 | -61.63% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $4.15 | +21,586.75% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $76.07 | -53.99% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $0.98 | +1,941.02% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $64.40
Upside: -2.17%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $21.64
Upside: +112.57%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $396.48
Upside: -25.34%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $115.76
Upside: -3.25%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $19.46
Upside: +347.07%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.45
Upside: +838.78%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $35.93
Upside: -44.34%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $5.82
Upside: +638.83%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $38.28
Upside: -16.41%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $4.24
Upside: +418.87%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $31.58
Upside: -39.84%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $3.35
Upside: +377.61%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $482.13
Upside: -61.63%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $4.15
Upside: +21,586.75%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $76.07
Upside: -53.99%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $0.98
Upside: +1,941.02%